Guggenheim Capital LLC Invests $450,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Guggenheim Capital LLC acquired a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 13,703 shares of the biopharmaceutical company's stock, valued at approximately $450,000.

Other large investors have also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. raised its stake in Agios Pharmaceuticals by 7.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock valued at $194,000 after purchasing an additional 394 shares during the last quarter. Federated Hermes Inc. lifted its stake in shares of Agios Pharmaceuticals by 4.4% during the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after purchasing an additional 582 shares during the period. KBC Group NV boosted its holdings in shares of Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 611 shares during the last quarter. Alliancebernstein L.P. increased its stake in Agios Pharmaceuticals by 1.2% in the fourth quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock valued at $2,021,000 after purchasing an additional 708 shares during the last quarter. Finally, Atria Investments Inc lifted its position in Agios Pharmaceuticals by 6.9% during the fourth quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock worth $373,000 after buying an additional 737 shares during the period.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now directly owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.93% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on AGIO. Scotiabank dropped their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research note on Friday. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective on the stock. Finally, StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Agios Pharmaceuticals Price Performance

Shares of AGIO stock traded down $0.17 on Friday, hitting $30.78. 99,200 shares of the stock traded hands, compared to its average volume of 703,671. The company's fifty day moving average is $29.91 and its 200 day moving average is $37.92. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The company has a market capitalization of $1.78 billion, a PE ratio of 2.71 and a beta of 0.83.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. As a group, equities research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.